Status:
COMPLETED
Assessment of Grazax® Treatment Compliance
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial is performed to assess whether the Grazax® treatment compliance can be improved by use of a compliance device (Memozax®).
Eligibility Criteria
Inclusion
- Grass pollen induced rhinoconjunctivitis
- Males and females, 18-65 years of age
- Positive skin prick test
Exclusion
- Previous treatment with grass pollen allergen
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00293046
Start Date
February 1 2006
End Date
October 1 2007
Last Update
September 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allgergie - Ambulatorium Rennweg
Vienna, Austria, 1030